Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

James Mark Cleary, Ph.D., M.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Sep 23. PMID: 34554208.
    Citations: 1     Fields:    
  2. de Klerk LK, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJ. Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. J Immunother Cancer. 2021 09; 9(9). PMID: 34593617.
    Citations:    Fields:    
  3. Monjazeb AM, Giobbie-Hurder A, Lako A, Thrash EM, Brennick RC, Kao KZ, Manuszak C, Gentzler RD, Tesfaye A, Jabbour SK, Alese OB, Rahma OE, Cleary JM, Sharon E, Mamon HJ, Cho M, Streicher H, Chen HX, Ahmed MM, Mariño-Enríquez A, Kim-Schulze S, Gnjatic S, Maverakis E, Marusina AI, Merleev AA, Severgnini M, Pfaff KL, Lindsay J, Weirather JL, Ranasinghe S, Spektor A, Rodig SJ, Hodi FS, Schoenfeld JD. Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4940. PMID: 34470811.
    Citations:    Fields:    
  4. Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 05; 5(1):74. PMID: 34354225.
    Citations:    
  5. Cleary JM, Wolpin BM, Dougan SK, Raghavan S, Singh H, Huffman B, Sethi NS, Nowak JA, Shapiro GI, Aguirre AJ, D'Andrea AD. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 Jul 20. PMID: 34285063.
    Citations: 1     Fields:    
  6. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 07 03; 398(10294):27-40. PMID: 34102137.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  7. Kwekkeboom K, Serlin RC, Ward SE, LeBlanc TW, Ogunseitan A, Cleary J. Revisiting patient-related barriers to cancer pain management in the context of the US opioid crisis. Pain. 2021 06 01; 162(6):1840-1847. PMID: 33337597.
    Citations:    Fields:    Translation:HumansPHPublic Health
  8. Sridharan V, Mino-Kenudson M, Cleary JM, Rahma OE, Perez K, Clark JW, Clancy TE, Rubinson DA, Goyal L, Bazerbachi F, Visrodia KH, Qadan M, Parikh A, Ferrone CR, Casey BW, Fernandez-Del Castillo C, Ryan DP, Lillemoe KD, Warshaw AL, Krishnan K, Hernandez-Barco YG. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021 May 15. PMID: 34023183.
    Citations:    Fields:    
  9. Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM. FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 Oct; 11(10):2488-2505. PMID: 33926920.
    Citations: 2     Fields:    
  10. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 04 01; 384(13):1191-1203. PMID: 33789008.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  11. Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist. 2021 07; 26(7):610-618. PMID: 33604969.
    Citations:    Fields:    Translation:Humans
  12. Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res. 2021 Jun 01; 27(11):2996-3004. PMID: 33637626.
    Citations:    Fields:    
  13. Monjazeb AM, Giobbie-Hurder A, Lako A, Thrash EM, Brennick RC, Kao KZ, Manuszak C, Gentzler RD, Tesfaye A, Jabbour SK, Alese OB, Rahma OE, Cleary JM, Sharon E, Mamon HJ, Cho M, Streicher H, Chen HX, Ahmed MM, Mariño-Enríquez A, Kim-Schulze S, Gnjatic S, Maverakis E, Marusina AI, Merleev AA, Severgnini M, Pfaff KL, Lindsay J, Weirather JL, Ranasinghe S, Spektor A, Rodig SJ, Hodi SF, Schoenfeld JD. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 May 01; 27(9):2470-2480. PMID: 33568343.
    Citations: 1     Fields:    
  14. Johnson S, Tittenbrun Z, Romero Y, Torode J, Frech S, Abdel-Wahab M, Juric A, Stevens L, Bray F, Piñeros M, Cleary J, Mattfeld E, Ilbawi A, Mikkelsen B. The World Cancer Declaration: time to consolidate wins and work towards 2025. Lancet Oncol. 2021 03; 22(3):296-298. PMID: 33548178.
    Citations: 2     Fields:    Translation:Humans
  15. Singh H, Li YY, Spurr LF, Shinagare AB, Abhyankar R, Reilly E, Brais LK, Nag A, Ducar MD, Thorner AR, Shapiro GI, Keller RB, Siletti C, Clark JW, Farago AF, Lin JJ, Demetri GD, Gujrathi R, Kulke MH, MacConaill LE, Ligon AH, Sicinska E, Meyerson ML, Meyerhardt JA, Cherniack AD, Wolpin BM, Ng K, Giannakis M, Hornick JL, Cleary JM. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 03 15; 27(6):1695-1705. PMID: 33414136.
    Citations: 1     Fields:    
  16. Hirner J, Cleary JM, Sheets A, Murphy G, LeBoeuf N. Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis. JAMA Dermatol. 2021 01 01; 157(1):119-121. PMID: 33052389.
    Citations:    Fields:    Translation:Humans
  17. Brown JC, Rosenthal MH, Ma C, Zhang S, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin B, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Zheng H, Hollis BW, Fuchs CS, Ng K, Meyerhardt JA. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. Cancers (Basel). 2020 Nov 20; 12(11). PMID: 33233566.
    Citations:    
  18. Razak AR, Cleary JM, Moreno V, Boyer M, Calvo Aller E, Edenfield W, Tie J, Harvey RD, Rutten A, Shah MA, Olszanski AJ, Jäger D, Lakhani N, Ryan DP, Rasmussen E, Juan G, Wong H, Soman N, Smit MD, Nagorsen D, Papadopoulos KP. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2). PMID: 33046621.
    Citations: 13     Fields:    Translation:Humans
  19. Bhola PD, Ahmed E, Guerriero JL, Sicinska E, Su E, Lavrova E, Ni J, Chipashvili O, Hagan T, Pioso MS, McQueeney K, Ng K, Aguirre AJ, Cleary JM, Cocozziello D, Sotayo A, Ryan J, Zhao JJ, Letai A. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Sci Signal. 2020 06 16; 13(636). PMID: 32546544.
    Citations: 9     Fields:    
  20. Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD. Biomarker-Guided Development of DNA Repair Inhibitors. Mol Cell. 2020 06 18; 78(6):1070-1085. PMID: 32459988.
    Citations: 23     Fields:    Translation:HumansAnimalsCells
  21. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807. PMID: 32416072.
    Citations: 78     Fields:    Translation:HumansCTClinical Trials
  22. Cleary JM, Calvo E, Moreno V, Juric D, Shapiro GI, Vanderwal CA, Hu B, Gifford M, Barch D, Roberts-Rapp L, Ansell PJ, Xiong H, Ocampo C, Tolcher AW. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Invest New Drugs. 2020 10; 38(5):1483-1494. PMID: 32189093.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  23. Bekaii-Saab T, Ou F, Anderson D, Ahn D, Boland P, Ciombor K, Jacobs N, Desnoyers R, Cleary J, Meyers J, Chiorean E, Pedersen K, Barzi A, Sloan J, McCune J, Lacouture M, Lenz H, Grothey A. Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Ann Oncol. 2018 Jun; 29 Suppl 5:v105. PMID: 32176993.
    Citations:    
  24. Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argilés G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020 01; 31(1):88-95. PMID: 31912801.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  25. Matos I, Goyal L, Cleary J, Voss M, Oh D, Bernstam FM, Ng C, Iyer G, Ishii N, Hu Y, Chessex AV, Pokorska-Bocci A, Nicolas V, Kirpicheva Y, Zanna C, Flaherty K, Tabernero J, Hyman D. Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Ann Oncol. 2019 Jul; 30 Suppl 4:iv122-iv123. PMID: 32085006.
    Citations:    
  26. Harding J, Cleary J, Shapiro G, Braña I, Moreno V, Quinn D, Borad M, Loi S, Spanggaard I, Stemmer S, Dujka M, Cutler R, Xu F, Eli L, Macia S, Lalani A, Bryce R, Bernstam FM, Solit D, Hyman D, Piha-Paul S. Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. Ann Oncol. 2019 Jul; 30 Suppl 4:iv127. PMID: 32085018.
    Citations:    
  27. Lowery MA, Burris HA, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019 09; 4(9):711-720. PMID: 31300360.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  28. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 08; 20(8):1070-1082. PMID: 31262657.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  29. Shapiro GI, LoRusso P, Kwak E, Pandya S, Rudin CM, Kurkjian C, Cleary JM, Pilat MJ, Jones S, de Crespigny A, Fredrickson J, Musib L, Yan Y, Wongchenko M, Hsieh HJ, Gates MR, Chan IT, Bendell J. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. Invest New Drugs. 2020 04; 38(2):419-432. PMID: 31020608.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  30. Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 04 09; 321(14):1370-1379. PMID: 30964527.
    Citations: 47     Fields:    Translation:HumansCTClinical Trials
  31. Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221. PMID: 30913304.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  32. Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR, Ishii N, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Vaslin Chessex A, Zanna C, Flaherty KT, Baselga J. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clin Cancer Res. 2019 05 01; 25(9):2699-2707. PMID: 30745300.
    Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
  33. Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111. PMID: 29903880.
    Citations: 78     Fields:    Translation:HumansCells
  34. Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215. PMID: 29101162.
    Citations: 104     Fields:    Translation:HumansAnimalsCells
  35. Mita MM, Mita AC, Moseley JL, Poon J, Small KA, Jou YM, Kirschmeier P, Zhang D, Zhu Y, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig SJ, Bannerji R, Shapiro GI. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer. 2017 Oct 24; 117(9):1258-1268. PMID: 28859059.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  36. Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, Chen S, Boskovic ZV, Javaid S, Huang C, Wu X, Tseng YY, Roider EM, Gao D, Cleary JM, Wolpin BM, Mesirov JP, Haber DA, Engelman JA, Boehm JS, Kotz JD, Hon CS, Chen Y, Hahn WC, Levesque MP, Doench JG, Berens ME, Shamji AF, Clemons PA, Stockwell BR, Schreiber SL. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017 07 27; 547(7664):453-457. PMID: 28678785.
    Citations: 274     Fields:    Translation:HumansCells
  37. Argilés G, Saro J, Segal NH, Melero I, Ros W, Marabelle A, Rodriguez ME, Albanell J, Calvo E, Moreno V, Cleary JM, Eder P, Paz-Ares L, Hurwitz H, Bacac M, Perro M, Bouseida S, Sandoval F, Sabanes Bove D, Sreckovic S, Jamois C, Silva A, Klein C, Umana P, Karanikas V, Tabernero J. LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). Ann Oncol. 2017 Jun 01; 28(suppl_3). PMID: 30052786.
    Citations:    Fields:    
  38. Argilés G, Saro J, Segal NH, Melero I, Ros W, Marabelle A, Rodriguez ME, Albanell J, Calvo E, Moreno V, Cleary JM, Eder P, Paz-Ares L, Hurwitz H, Bacac M, Perro M, Bouseida S, Sandoval F, Sabanes Bove D, Sreckovic S, Jamois C, Silva A, Klein C, Umana P, Karanikas V, Tabernero J. Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). Ann Oncol. 2017 Jun; 28 Suppl 3:iii151. PMID: 32135795.
    Citations:    
  39. Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017 06 01; 123(11):1979-1988. PMID: 28192597.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  40. Cleary JM, Rosen LS, Yoshida K, Rasco D, Shapiro GI, Sun W. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. Invest New Drugs. 2017 04; 35(2):189-197. PMID: 28111727.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  41. Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CL. Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clin Cancer Res. 2017 Jul 15; 23(14):3520-3528. PMID: 28031425.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  42. Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. PMID: 27882345.
    Citations: 105     Fields:    Translation:Humans
  43. Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs CS, Martin NE, Getz G, Carter S, Mamon HJ, Hornick JL, Van Allen EM, D'Andrea AD. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clin Cancer Res. 2017 Jun 15; 23(12):3214-3222. PMID: 27852700.
    Citations: 17     Fields:    Translation:Humans
  44. Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. Invest New Drugs. 2017 02; 35(1):68-78. PMID: 27853996.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  45. Cleary JM, Mamon HJ, Szymonifka J, Bueno R, Choi N, Donahue DM, Fidias PM, Gaissert HA, Jaklitsch MT, Kulke MH, Lynch TP, Mentzer SJ, Meyerhardt JA, Swanson RS, Wain J, Fuchs CS, Enzinger PC. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016 07 13; 16:468. PMID: 27412386.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  46. LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 07 01; 22(13):3227-37. PMID: 26842236.
    Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
  47. Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Feb 15; 22(4):847-57. PMID: 26423795.
    Citations: 59     Fields:    Translation:HumansCTClinical Trials
  48. Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, Pandya SS, Bedard PL, Pierce KJ, Houk B, Roberts WG, Shreeve SM, Shapiro GI. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015 10; 33(5):1100-7. PMID: 26334219.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  49. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14; 372(20):1909-19. PMID: 25970050.
    Citations: 282     Fields:    Translation:HumansCTClinical Trials
  50. Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, Pedersen M, Ansell P, Ames W, Xiong H, Munasinghe W, Dudley M, Reilly EB, Holen K, Humerickhouse R. A phase 1 study of ABT-806 in subjects with advanced solid tumors. Invest New Drugs. 2015 Jun; 33(3):671-8. PMID: 25895099.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  51. Tirumani SH, Kim KW, Nishino M, Howard SA, Krajewski KM, Jagannathan JP, Cleary JM, Ramaiya NH, Shinagare AB. Update on the role of imaging in management of metastatic colorectal cancer. Radiographics. 2014 Nov-Dec; 34(7):1908-28. PMID: 25384292.
    Citations: 19     Fields:    Translation:Humans
  52. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral ?-secretase inhibitor PF-03084014. Clin Cancer Res. 2015 Jan 01; 21(1):60-7. PMID: 25231399.
    Citations: 72     Fields:    Translation:HumansCTClinical Trials
  53. Cleary JM, Lima CM, Hurwitz HI, Montero AJ, Franklin C, Yang J, Graham A, Busman T, Mabry M, Holen K, Shapiro GI, Uronis H. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs. 2014 Oct; 32(5):937-45. PMID: 24916770.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  54. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, Fuchs CS, McCleary NJ, Meyerhardt JA, Ng K, Schrag D, Sikora AL, Spicer BA, Killion L, Mamon H, Kimmelman AC. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8. PMID: 24821822.
    Citations: 117     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  55. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53. PMID: 24625776.
    Citations: 130     Fields:    Translation:HumansCTClinical Trials
  56. Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark JW, Shapiro GI, Armand P. Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):323-6; quiz 326. PMID: 24616538.
    Citations: 4     Fields:    Translation:Humans
  57. Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014 Jan 10; 32(2):68-75. PMID: 24323026.
    Citations: 66     Fields:    Translation:HumansCellsCTClinical Trials
  58. Howard SA, Krajewski KM, Thornton E, Jagannathan JP, O'Regan K, Cleary J, Ramaiya N. Decade of molecular targeted therapy: abdominal manifestations of drug toxicities--what radiologists should know. AJR Am J Roentgenol. 2012 Jul; 199(1):58-64. PMID: 22733894.
    Citations: 9     Fields:    Translation:Humans
  59. Thornton E, Howard SA, Jagannathan J, Krajewski KM, Shinagare AB, O'Regan K, Cleary JM, Ramaiya NH. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol. 2012 Oct; 85(1018):1420-6. PMID: 22674709.
    Citations: 6     Fields:    Translation:Humans
  60. Cho DC, Heath EI, Cleary JM, Kwak EL, Gandhi L, Lawrence DP, Zack C, Teofilovici F, Bradley R, Karol MD, Shapiro G, LoRusso P. A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. J Clin Oncol. 2011 May 20; 29(15_suppl):3051. PMID: 28022585.
    Citations:    
  61. Jones SF, Shapiro G, Bendell JC, Chen EX, Bedard P, Cleary JM, Pandya S, Pierce KJ, Houk B, Hosea N, Zandi KS, Roberts WG, Shreeve SM, Siu LL. Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3002. PMID: 28022183.
    Citations:    
  62. Shapiro G, LoRusso P, Kwak EL, Cleary JM, Musib L, Jones C, de Crespigny A, Belvin M, McKenzie M, Gates MR, Chan IT, Bendell JC. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3005. PMID: 28022184.
    Citations:    
  63. Ho AL, Bendell JC, Cleary JM, Schwartz GK, Burris HA, Oakes P, Agbo F, Barker PN, Senderowicz AM, Shapiro G. Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3033. PMID: 28022653.
    Citations:    
  64. Urban T, Sadow CA, Cleary JM, Harris GJ, Van Den Abbeele AD. Impact of RECIST 1.1 modifications on clinical trial eligibility. J Clin Oncol. 2011 May 20; 29(15_suppl):e16555. PMID: 28022052.
    Citations:    
  65. Ghamande SA, Lin C, Cho DC, Coleman TA, Chaudhary I, Cleary JM, Silverman MH, Kuo M, Mach W, Tseng Y, Hsu SC, Goel S. A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):e13618. PMID: 28023558.
    Citations:    
  66. Messersmith WA, LoRusso P, Cleary JM, Dasari A, Zhang X, Shaik MN, Courtney RD, Randolph S, Shapiro G. A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3100. PMID: 28022754.
    Citations:    
  67. Kauh JS, Shapiro G, Cohen RB, Clark JW, Harvey RD, Cleary JM, Mahalingam D, Kuan S, McDonald A, Berger A, Dezube B, Sarantopoulos J. MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules. J Clin Oncol. 2011 May 20; 29(15_suppl):3013. PMID: 28022162.
    Citations:    
  68. Cleary JM, Rocha Lima CM, Hurwitz H, Montero AJ, Shapiro G, Franklin C, Yang J, Graham AM, Busman T, Mabry M, Holen KD, Krivoshik A, Humerickhouse R, Uronis H. Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3067. PMID: 28022570.
    Citations:    
  69. Mita MM, Mita AC, Moseley J, Poon J, Small KA, Jou Y, Kirschmeier P, Zhang D, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig S, Bannerji R, Shapiro G. A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. J Clin Oncol. 2011 May 20; 29(15_suppl):3080. PMID: 28022511.
    Citations:    
  70. Gandhi L, Bahleda R, Cleary JM, Hollebecque A, Kwak EL, Pandya S, Tolaney S, Abbas R, Ananthakrishnan R, Berkenblit A, Boni J, Clancy J, Turnbull KW, VoVan M, Shapiro G, Soria J. Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3027. PMID: 28022681.
    Citations:    
  71. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, Escudier B, Rini BI. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010 Dec 01; 116(23):5400-6. PMID: 21105118.
    Citations: 41     Fields:    Translation:Humans
  72. Cleary JM, Sadow PM, Randolph GW, Palmer EL, Lynch TP, Nikiforov YE, Wirth LJ. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol. 2010 Aug 10; 28(23):e390-2. PMID: 20567012.
    Citations: 6     Fields:    Translation:Humans
  73. Cleary JM, Shapiro GI. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep. 2010 Mar; 12(2):87-94. PMID: 20425592.
    Citations: 29     Fields:    Translation:HumansAnimals
  74. Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist. 2009 Nov; 14(11):1095-105. PMID: 19880627.
    Citations: 25     Fields:    Translation:Humans
  75. Yowe D, Weich N, Prabhudas M, Poisson L, Errada P, Kapeller R, Yu K, Faron L, Shen M, Cleary J, Wilkie TM, Gutierrez-Ramos C, Hodge MR. RGS18 is a myeloerythroid lineage-specific regulator of G-protein-signalling molecule highly expressed in megakaryocytes. Biochem J. 2001 Oct 01; 359(Pt 1):109-18. PMID: 11563974.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  76. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998 Apr 15; 90(8):611-6. PMID: 9554444.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  77. Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol. 1997 Feb; 15(2):781-9. PMID: 9053505.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  78. Vartak NB, Lin CC, Cleary JM, Fagan MJ, Saier MH. Glucose metabolism in 'Sphingomonas elodea': pathway engineering via construction of a glucose-6-phosphate dehydrogenase insertion mutant. Microbiology (Reading). 1995 Sep; 141 ( Pt 9):2339-50. PMID: 7496544.
    Citations: 3     Translation:Cells
  79. Hirano M, Cleary JM, Stewart AM, Lincoff NS, Odel JG, Santiesteban R, Santiago Luis R. Mitochondrial DNA mutations in an outbreak of optic neuropathy in Cuba. Neurology. 1994 May; 44(5):843-5. PMID: 8190285.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
  80. Harding NE, Raffo S, Raimondi A, Cleary JM, Ielpi L. Identification, genetic and biochemical analysis of genes involved in synthesis of sugar nucleotide precursors of xanthan gum. J Gen Microbiol. 1993 Mar; 139(3):447-57. PMID: 20050414.
    Citations: 8     Fields:    Translation:Cells
  81. Marzocca MP, Harding NE, Petroni EA, Cleary JM, Ielpi L. Location and cloning of the ketal pyruvate transferase gene of Xanthomonas campestris. J Bacteriol. 1991 Dec; 173(23):7519-24. PMID: 1657892.
    Citations: 9     Fields:    Translation:Cells
  82. Zyskind JW, Cleary JM, Brusilow WS, Harding NE, Smith DW. Chromosomal replication origin from the marine bacterium Vibrio harveyi functions in Escherichia coli: oriC consensus sequence. Proc Natl Acad Sci U S A. 1983 Mar; 80(5):1164-8. PMID: 6338499.
    Citations: 79     Fields:    Translation:Cells
  83. Harding NE, Cleary JM, Smith DW, Michon JJ, Brusilow WS, Zyskind JW. Chromosomal replication origins (oriC) of Enterobacter aerogenes and Klebsiella pneumoniae are functional in Escherichia coli. J Bacteriol. 1982 Dec; 152(3):983-93. PMID: 6292170.
    Citations: 22     Fields:    Translation:Cells
  84. Cleary JM, Smith DW, Harding NE, Zyskind JW. Primary structure of the chromosomal origins (oriC) of Enterobacter aerogenes and Klebsiella pneumoniae: comparisons and evolutionary relationships. J Bacteriol. 1982 Jun; 150(3):1467-71. PMID: 7042695.
    Citations: 14     Fields:    Translation:Cells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Cleary's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (328)
Explore
_
Co-Authors (160)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.